title: [Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer and COPD.].
abstract: BACKGROUND
  To evaluate the clinical efficacy and the security of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer and COPD.
  
  
  METHODS
  Fifteen patients with advanced non-small cell lung cancer and COPD were treated with erlotinib 150 mg/d, and then the adverse reactions and clinical effects were recorded.
  
  
  RESULTS
  The effective rate was 20%. We analyzed the effective rate of stage III and IV, and there were no significant difference between the two (P=0.569). KPS was increased in 40% patients. Mild or moderate rash, diarrhea, nausea and vomiting were the main adverse reactions.
  
  
  CONCLUSIONS
  For elderly patients with advanced non-small cell lung cancer and COPD, the use of erlotinib might achieve better security and effectiveness.
authors: Department of Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China. zzq_9@sina.com.
authors: Qing
authors: Q
authors: Ma
authors: Li
authors: L
authors: Ma
authors: Yan
authors: Y
authors: Wang
authors: Fanlu
authors: F
authors: Meng
authors: Linglin
authors: L
authors: Zou
authors: Huiling
authors: H
authors: Zhang